Log in
NASDAQ:PODD

Insulet Competitors

$265.89
+0.65 (+0.25 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$261.28
Now: $265.89
$268.80
50-Day Range
$215.97
MA: $247.12
$265.24
52-Week Range
$121.00
Now: $265.89
$269.42
Volume338,177 shs
Average Volume525,225 shs
Market Capitalization$17.53 billion
P/E Ratio949.64
Dividend YieldN/A
Beta0.73

Competitors

Insulet (NASDAQ:PODD) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying PODD stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Insulet, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

Abbott Laboratories has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Abbott Laboratories and Insulet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Insulet110702.33

Abbott Laboratories currently has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Insulet has a consensus target price of $235.1875, suggesting a potential downside of 11.55%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, equities analysts clearly believe Abbott Laboratories is more favorable than Insulet.

Insider & Institutional Ownership

63.9% of Abbott Laboratories shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 1.1% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Abbott Laboratories and Insulet's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Insulet$738.20 million23.75$11.60 million$0.191,399.42

Abbott Laboratories has higher revenue and earnings than Insulet. Abbott Laboratories is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Insulet2.20%10.96%1.81%

Summary

Abbott Laboratories beats Insulet on 12 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

Medtronic has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Medtronic and Insulet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Insulet110702.33

Medtronic currently has a consensus target price of $118.1538, suggesting a potential upside of 6.47%. Insulet has a consensus target price of $235.1875, suggesting a potential downside of 11.55%. Given Medtronic's stronger consensus rating and higher probable upside, equities analysts clearly believe Medtronic is more favorable than Insulet.

Insider & Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 1.1% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Medtronic and Insulet's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Insulet$738.20 million23.75$11.60 million$0.191,399.42

Medtronic has higher revenue and earnings than Insulet. Medtronic is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Insulet2.20%10.96%1.81%

Summary

Medtronic beats Insulet on 10 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Stryker and Insulet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Insulet110702.33

Stryker currently has a consensus target price of $221.44, suggesting a potential downside of 4.97%. Insulet has a consensus target price of $235.1875, suggesting a potential downside of 11.55%. Given Stryker's stronger consensus rating and higher probable upside, equities analysts clearly believe Stryker is more favorable than Insulet.

Insider & Institutional Ownership

71.0% of Stryker shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 1.1% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Stryker and Insulet's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Insulet$738.20 million23.75$11.60 million$0.191,399.42

Stryker has higher revenue and earnings than Insulet. Stryker is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Insulet2.20%10.96%1.81%

Summary

Stryker beats Insulet on 13 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 1.1% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Intuitive Surgical and Insulet's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
Insulet$738.20 million23.75$11.60 million$0.191,399.42

Intuitive Surgical has higher revenue and earnings than Insulet. Intuitive Surgical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Intuitive Surgical and Insulet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Insulet110702.33

Intuitive Surgical currently has a consensus target price of $718.2778, suggesting a potential downside of 0.11%. Insulet has a consensus target price of $235.1875, suggesting a potential downside of 11.55%. Given Intuitive Surgical's stronger consensus rating and higher probable upside, equities analysts clearly believe Intuitive Surgical is more favorable than Insulet.

Profitability

This table compares Intuitive Surgical and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Insulet2.20%10.96%1.81%

Volatility & Risk

Intuitive Surgical has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Summary

Intuitive Surgical beats Insulet on 12 of the 14 factors compared between the two stocks.

Insulet (NASDAQ:PODD) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. 1.1% of Insulet shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Insulet and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$738.20 million23.75$11.60 million$0.191,399.42
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Insulet. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Insulet and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insulet110702.33
Becton, Dickinson and07712.60

Insulet presently has a consensus price target of $235.1875, suggesting a potential downside of 11.55%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Insulet.

Profitability

This table compares Insulet and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insulet2.20%10.96%1.81%
Becton, Dickinson and5.11%13.30%5.60%

Risk & Volatility

Insulet has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

Becton, Dickinson and beats Insulet on 11 of the 14 factors compared between the two stocks.

Insulet (NASDAQ:PODD) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of Insulet shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Insulet and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$738.20 million23.75$11.60 million$0.191,399.42
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Insulet. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Insulet and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insulet110702.33
Edwards Lifesciences251302.55

Insulet presently has a consensus price target of $235.1875, suggesting a potential downside of 11.55%. Edwards Lifesciences has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Insulet.

Profitability

This table compares Insulet and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insulet2.20%10.96%1.81%
Edwards Lifesciences18.18%29.00%18.10%

Risk & Volatility

Insulet has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Insulet on 12 of the 14 factors compared between the two stocks.


Insulet Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.